Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Tectonic Therapeutic Inc. | RXFP1 Agonist (TX45 – Fc-relaxin) | Heart Failure with Preserved Ejection Fraction (HFpEF) | Phase 2 | Enrollment Initiation | Intravenous | Cardiology |
| Tectonic Therapeutic Inc. | TX45 - (APEX) | Group 2 Pulmonary Hypertension | Phase 2 | Ongoing | Oral | Cardiology |
| Teleflex Incorporated | BiPASS (Illuccix) | Biopsy of the Prostate Avoidance Stratification Study | Phase 3 | Ongoing | Intravenous | Oncology |
| Telix Pharmaceuticals Limited | TLX101-CDx | Progressive or recurrent glioma | NDA Filing | Ongoing | Intravenous | Oncology |
| Telix Pharmaceuticals Limited | TLX591-CDx | Prostate cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Tempest Therapeutics Inc. | Amezalpat (TPST-1120) with atezolizumab and bevacizumab - (TPST-1120-301) | Hepatocellular carcinoma (HCC) | Phase 3 | Trial Planned | Intravenous | Oncology |
| Tempest Therapeutics Inc. | TPST-1495 | Familial Adenomatous Polyposis (FAP) | Phase 2 | Study May Proceed Letter | oral | Genetic Disorder |
| Tenax Therapeutics Inc. | TNX-103 - (LEVEL-2) | Heart failure with preserved ejection fraction (PH-HFpEF) | Phase 3 | Enrollment Initiation | Oral | Cardiology |
